{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:27:59Z","timestamp":1792686479393,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.amjms.2021.04.010","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T05:29:27Z","timestamp":1619242167000},"page":"321-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma"],"prefix":"10.1016","volume":"362","author":[{"given":"Toshiyuki","family":"Kita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2021.04.010_bib0001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2021.04.010_bib0002","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2021.04.010_bib0003","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2021.04.010_bib0004","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2021.04.010_bib0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Alvarez-Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2021.04.010_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2021.04.010_bib0007","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/imj.12823","article-title":"Recent advances in polymyalgia rheumatica","volume":"45","author":"Owen","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.amjms.2021.04.010_bib0008","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2021.04.010_bib0009","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.amjms.2021.04.010_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjms.2021.04.010_bib0011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2021.04.010_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjms.2021.04.010_bib0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.amjms.2021.04.010_bib0014","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-017-2410-x","article-title":"Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment","volume":"143","author":"Nakamagoe","year":"2017","journal-title":"J Cancer Res Clin"},{"key":"10.1016\/j.amjms.2021.04.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.amjms.2021.04.010_bib0016","first-page":"907","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2021.04.010_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CJI.0000000000000163","article-title":"Nivolumab causing a polymyalgia rheumatica in a patient with a squamous non\u2013small cell lung cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.amjms.2021.04.010_bib0018","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2021.04.010_bib0019","first-page":"394","article-title":"A case of lung adenocarcinoma with long-term anti-tumor maintenance after the discontinuation of nivolumab due to polymyalgia rheumatica","volume":"7","author":"Murayama","year":"2018","journal-title":"Ann Jap Resp Soc"},{"key":"10.1016\/j.amjms.2021.04.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.amjms.2021.04.010_bib0021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014Clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2021.04.010_bib0022","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjms.2021.04.010_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962921001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:39:48Z","timestamp":1757702388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962921001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0002962921001464"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2021.04.010","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2021.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}